IL2 and peeling skin syndrome: We have shown that LD-IL-2 confers benefits for the treatment of patients with pSS and resulted in a significant clinical improvement in ESSDAI, ESSPRI, and SF-36 MCS scores, as well as organ involvement including pulmonary lesions among patients with pSS.